Article
Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications.
Expert opinion on therapeutic targets - 1 Apr 2021
Gonzales Fanny, Barthélémy Adeline, Peyrouze Pauline, Fenwarth Laurène, Preudhomme Claude, Duployez Nicolas, Cheok Meyling H
Abstract excerpt
Introduction: RUNX1 is an essential transcription factor for normal and malignant hematopoiesis. RUNX1 forms a heterodimeric complex with CBFB. Germline mutations and somatic alterations (i.e. translocations, mutations and abnormal expression) are frequently associated with acute myeloid leukemia (AML) with RUNX1 mutations conferring unfavorable prognosis. Therefore, RUNX1 constitutes a potential innovative and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.